NEXGEL, Inc. (NXGL) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations.
Analysis Summary
NEXGEL, Inc. reported revenue of $11.4M in the most recent fiscal year, growing at a 5-year CAGR of 76.1%.
Trailing-twelve-month margins: gross margin 35.1%, operating margin -44.8%, net margin -51.3%.
At the current price of $0.26, NXGL has negative trailing earnings (P/E not meaningful) and an ROE of -133.10%. Market capitalisation stands at $2M.
Balance sheet quality for NXGL: current ratio of 1.5, net debt of $2.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.26 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.45 |
| EV / EBITDA | -4.57 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -133.10% |
| Return on Invested Capital | -41.80% |
| Return on Assets | -23.39% |
| Gross Margin | 35.07% |
| Operating Margin | -44.77% |
| Net Margin | -51.26% |
Financial Health
| Debt / Equity | 1.51 |
| Current Ratio | 0.43 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -1.25 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NXGL | NEXGEL, Inc. | $2M | 0.45 | -133.1% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Price Performance
| 1 month | -35.45% |
| 3 months | -56.15% |
| Year-to-date | -84.58% |
| 1 year | -90.07% |
| 3 years | -88.72% |
52-Week Range
| 52-week High | $2.89 |
| 52-week Low | $0.24 |
| Avg Volume (90d) | 588K |
Related companies: ENLV · FEMY · GDTC · HBIO · IINN · MLSS · MTVA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NXGL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks